Penpulimab Biosimilar – Anti-Pd-1 mAb – Research Grade

Description of Penpulimab Biosimilar - Anti-Pd-1 mAb - Research Grade

Introduction to Penpulimab Biosimilar – A Promising Anti-PD-1 mAb for Cancer Immunotherapy

Penpulimab Biosimilar, also known as Anti-PD-1 mAb, is a novel monoclonal antibody that has shown promising results in cancer immunotherapy. This biosimilar is designed to target and block the programmed cell death protein 1 (PD-1) pathway, which plays a critical role in suppressing the immune response against cancer cells. In this article, we will delve into the structure, activity, and potential applications of Penpulimab Biosimilar as a research-grade antibody.

Structure of Penpulimab Biosimilar – A Monoclonal Antibody Against PD-1

Penpulimab Biosimilar is a recombinant humanized monoclonal antibody, produced by genetic engineering techniques. It is composed of two identical heavy chains and two identical light chains, each containing a variable and a constant region. The variable region of the antibody is responsible for recognizing and binding to its target, PD-1, while the constant region provides stability and effector functions. The structure of Penpulimab Biosimilar is similar to the endogenous antibody, making it less immunogenic and more suitable for therapeutic use.

Mechanism of Action – How Penpulimab Biosimilar Blocks PD-1 Pathway

PD-1 is a checkpoint receptor expressed on the surface of T cells, which inhibits their activity upon binding to its ligands, PD-L1 and PD-L2. This interaction helps cancer cells evade the immune system and grow unchecked. Penpulimab Biosimilar works by binding to PD-1, preventing its interaction with PD-L1 and PD-L2. This blockade releases the brakes on the immune response, allowing T cells to attack and kill cancer cells. Moreover, Penpulimab Biosimilar can also induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the destruction of PD-1-expressing cancer cells.

Title: Potential Applications of Penpulimab Biosimilar – A Research-Grade Antibody

Penpulimab Biosimilar has shown promising results in preclinical studies and is currently undergoing clinical trials for various types of cancer, including melanoma, lung cancer, and bladder cancer. It has also been granted orphan drug designation by the FDA for the treatment of hepatocellular carcinoma. As a research-grade antibody, Penpulimab Biosimilar can be used to study the PD-1 pathway and its role in cancer immunotherapy. It can also serve as a positive control in PD-1 pathway inhibition assays and as a tool for the development of other therapeutic antibodies targeting PD-1.

Advantages of Penpulimab Biosimilar – A Cost-Effective and Safe Option

One of the major advantages of Penpulimab Biosimilar is its cost-effectiveness. Being a biosimilar, it is less expensive to produce compared to the originator antibody, making it more accessible for patients. Moreover, as a research-grade antibody, it can be used in large quantities without the risk of depleting the limited supply of therapeutic antibodies. Another advantage is its safety profile, which has been demonstrated in preclinical and clinical studies. Penpulimab Biosimilar has shown no significant adverse effects, making it a promising option for cancer immunotherapy.

Conclusion – The Potential of Penpulimab Biosimilar in Cancer Immunotherapy

In conclusion, Penpulimab Biosimilar is a promising anti-PD-1 mAb with a similar structure and mechanism of action to the originator antibody. Its potential applications as a research-grade antibody and as a cost-effective and safe option for cancer immunotherapy make it a valuable asset in the fight against cancer. With ongoing clinical trials and further research, Penpulimab Biosimilar has the potential to improve outcomes for cancer patients and contribute to the advancement of cancer immunotherapy.

Penpulimab Biosimilar - Anti-Pd-1 mAb binds to CD279 Recombinant Protein in indirect ELISA Assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind to Penpulimab Biosimilar - Anti-Pd-1 mAb (cat. No.PX-TA1638) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450